Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) – Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2 – Yahoo Finance

Executive Summary According to the report published in September 2022, the global Pain Management Drugs market was valued at USD 82. 12 million in the year 2021 with Americas leading the regional market share.
New York, Oct. 06, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Global Pain Management Drugs Market Demand and Pipeline Insights (2022 Edition) – Analysis By Drug Type, Route of Administration, End-Use, Availability, Sales Channel, By Region, By Country: Market Insights & Forecast with Impact of COVID-19 (2023-2028)” – https://www.reportlinker.com/p06326340/?utm_source=GNW

The global Pain Management Drugs Market is driven by an increasing number of Chronic Pain diseases and the prevalence of cancer pain worldwide. Additionally, a growing population in which the number of geriatric population is high in several developing countries is anticipated to propel the growth of the global Pain Management drugs market.

Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This is likely to drive demand for many Pain Management drugs for advanced stages of cancer, chronic pain conditions and post-operative pain management drugs.

The COVID- 19 pandemic had a mixed impact on the Global Pain Management Drugs market by affecting the drug supply chain dramatically which led to hindrances in the production and sale of opiates which are the most prominent Pain management drug in the market in key producing countries such as Afghanistan and Myanmar. Paracetamol was recommended for use by various healthcare authorities across the world, to manage fever and mild pain in adults and children with COVID-19, which boosted the demand for the drug. Moreover, India and China being the chief API suppliers for Paracetamol drugs were unable to supply the APIs due to restrictions imposed due to COVID -19 which led to manufacturing restraints and shortages in many European countries.

Scope of the Report
• The report presents insights on the 28 major drug development pipelines for Pain Management.

• The report presents the analysis of the Pain Management Drugs Market for the historical period of 2018-2021, the estimated year 2022 and the forecast period of 2023-2028.

• The report analyses the Pain Management Drugs Market by Drug Type (Acetaminophen, Nonsteroidal anti-inflammatory drugs (NSAIDs), Narcotics, Others).

• The report analyses the Pain Management Drugs Market by Route of Administration (Topical, Intravenous, Oral, Others).

• The report analyses the Pain Management Drugs Market by End-use (Inflammation, Neuropathic Pain, Musculoskeletal Pain, Severe and Chronic Pain).

• The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription).

• The report analyses the Pain Management Drugs Market by Sales Channel (Retail Pharmacies, Hospital Pharmacies and E-commerce).

• The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

• The Global Pain Management Drugs Market has been analysed By Country (United States, Canada, Germany, U.K, France, Spain, Italy, China, Japan and India).

• The key insights of the report have been presented through the leading company shares. Also, the attractiveness of the market has been presented by region, by Drug Class, by Indication, by End User, by Formulation, and by Distribution Channel.

• Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.

• The report tracks competitive developments, strategies, and recent developments. The companies analysed in the report include Pfizer, Johnson and Johnson, GSK Plc., Bristol-Myers Squibb, AbbVie, Bayer, Boehringer Ingelheim, Novartis, Teva Pharmaceutical, Sanofi, Amgen.

Key Target Audience

• Pain Management Drugs Companies

• Healthcare and Pharmaceutical Companies

• Research and Development (R&D) Organizations

• Government Bodies & Regulating Authorities

• Investment Banks and Equity Firms
Read the full report: https://www.reportlinker.com/p06326340/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

Costco offers a very simple proposition to its members. Basically, Costco offers no frills — its stores aren't just called warehouses, they actually are warehouses — and items are basically just stacked on pallets. Costco also puts relentless pressure on its vendors to squeeze out every penny of cost from each item.
Investors are facing a storm of headwinds right now – a genuine bear market, stubbornly high inflation, rising interest rates, and increased fears of a recession in the near-term. However, Mary Callahan Erdoes, CEO of JPMorgan's Asset & Wealth Management division, advises investors to stay invested. "It's actually the easiest time in the world to find alpha — there is alpha everywhere… It's everywhere, because we are in such a state of change… While all the world is focused on all the black
(Bloomberg) — Signs are piling up that the tech downturn may be deeper and longer-lasting than feared. Most Read from BloombergMusk's Twitter Takeover Hits Snag Over Debt-Financing IssueKremlin Lets State Media Tell Some Truths About Putin’s Stalling WarNord Stream Leaks Caused by Detonations in Sign of SabotageBiden Says Putin Threats Real, Could Spark Nuclear ‘Armageddon’Trump Says US Agency Packed Top-Secret Documents. These Emails Suggest Otherwise.After years of record capital spending, ch
Frontline workers are stressed by the limited-time promotion that runs through the end of October.
(Bloomberg) — Sign up for our Middle East newsletter and follow us @middleeast for news on the region.Most Read from BloombergTrump Says US Agency Packed Top-Secret Documents. These Emails Suggest Otherwise.Nord Stream Leaks Caused by Detonations in Sign of SabotageSecretive Chip Startup May Help Huawei Circumvent US SanctionsKremlin Lets State Media Tell Some Truths About Putin’s Stalling WarStocks Slide for Second Day Ahead of Jobs Report: Markets WrapSaudi Arabia kept oil prices for its main
The CDC's latest report on COVID-19 vaccinations didn't provide enough fuel for shareholder optimism.
Eli Lilly said Thursday it plans to begin the process of asking the FDA to approve its obesity treatment. LLY stock rose on the news.
The chip industry is in the early stages of a cyclical downturn right now, and Micron itself announced a big hit to its revenue and profits is upcoming. New York state, where Micron plans on spending up to $100 billion over the next two decades on a new megafab. It's huge news for Micron, New York, and the whole semiconductor industry, which is still grappling with fallout from the pandemic and a shaky supply chain that is highly reliant on overseas fabs.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Gas prices are rising again, and this might be just the beginning.
CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam Therapeutics are part of the Zacks top Analyst Blog.
While the SPDR S&P Healthcare ETF is down 10% year to date, the SPDR S&P Biotech ETF has plummeted 29%. Investors should always keep the long-term potential of businesses in mind when investing in the stock market. Sunosi, purchased from Jazz Pharmaceuticals in May, has been Axsome's blockbuster drug.
(Bloomberg) — Commodities have opened the fourth quarter in some style, with prices set for the best weekly showing since March after OPEC+ agreed to chop oil supply. The coming week brings a host of signals on the outlook over the rest of the year and into 2023 before earnings season hits full flood. Most Read from BloombergMusk's Twitter Takeover Hits Snag Over Debt-Financing IssueKremlin Lets State Media Tell Some Truths About Putin’s Stalling WarNord Stream Leaks Caused by Detonations in Si
Oil prices have been all over the place this year. WTI, the primary U.S. oil price benchmark, started 2022 at around $75 a barrel before rocketing over $120 a barrel following Russia's invasion of Ukraine. The move could keep a floor under crude prices and potentially push them higher depending on demand and other supplies.
Warren Buffett has been making a bold bet on oil prices over the past year. While oil prices have cooled off on fears that we're about to enter a global recession, that slump has reversed recently thanks to OPEC.
CHICAGO (Reuters) -Tyson Foods Inc is joining other corporate heavyweights in moving jobs out of Illinois. The biggest U.S. meat company by sales said on Wednesday it will relocate all corporate employees from offices in Chicago and suburban Downers Grove, along with those in Dakota Dunes, South Dakota, to its headquarters in Springdale, Arkansas. It is the latest shakeup for Tyson, which has about 1,000 corporate employees in the Chicago-area and South Dakota offices.
These are the energy stocks with the best value, fastest growth, and most momentum for October 2022.
These are the utilities stocks with the best value, fastest growth, and most momentum for October 2022.
OPEC’s decision to lower output quota hay have a serious impact on crude supply this fall, providing further upward support for crude prices this winter
OPEC+ will cut oil production by 2 million barrels per day amid looming demand concerns and the ongoing friction between the West and Russia over the war in Ukraine.

source

Add a Comment

Your email address will not be published. Required fields are marked *